ATR

AptarGroup, Inc.

Industrial/Transportation


Presented:07/08/2020
Price:$112.93
Cap:$7.25B
Current Price:$168.68
Cap:$11.20B

Presented

Date07/08/2020
Price$112.93
Market Cap$7.25B
Ent Value$7.58B
P/E Ratio31.94x
Book Value$24.72
Div Yield1.28%
Shares O/S64.19M
Ave Daily Vol317,044
Short Int1.16%

Current

Price$168.68
Market Cap$11.20B
AptarGroup, Inc. develops manufactures and sales of consumer product dispensing systems. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Publicly traded companies mentioned herein: AptarGroup Inc (ATR), West Pharmaceutical Services Inc (WST)

Highlights

AptarGroup (ATR) represents an attractive risk/reward setup for bulls at $110 due to the underappreciated performance and value of its pharma business, which is masked by the more traditional food & beverage and beauty & home packaging operations. The presenter is long the stock and sees the potential for 35%+ upside as the story becomes clearer over the remainder of 2020. To arrive at a $150+ price target, the presenter assumes that 1) the pharma segment is worth 20x EBITDA, and 2) the remainder of the business is worth 10x - 11x EBITDA. There could be further upside potential if a nasal spray is the delivery mechanism for a COVID-19 vaccine (vs. an injection). Given ATR’s estimated 60% - 70% share of the nasal delivery market, this would potentially be a home run for the company.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.